Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 5/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 5/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | VDR | P11473 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1763716 | 0.90 | SLC9A1 (0.69) | SLC9A1CYP2C9CYP2C19CCR8THRB | |
| SCHEMBL12593251 | 0.88 | SLC9A1 (0.46) | SLC9A1CYP2C9CYP2C19CCR8SOS1 | |
| SCHEMBL1763568 | 0.86 | SLC9A1 (0.68) | SLC9A1FASN | |
| SCHEMBL1763532 | 0.86 | SLC9A1 (0.55) | SLC9A1CYP2C9CYP2C19THRBTHRA | |
| SCHEMBL7987294 | 0.81 | SLC9A1 (0.52) | SLC9A1KMT2AFASN | |
| SCHEMBL1763664 | 0.81 | SLC9A1 (0.51) | SLC9A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL12593546 | 0.80 | SLC9A1 (0.42) | SLC9A1CYP2C9CYP2C19SOS1KMT2A | |
| SCHEMBL12593226 | 0.80 | SLC9A1 (0.52) | SLC9A1CYP2C9CYP2C19SOS1POLB | |
| SCHEMBL7995334 | 0.79 | SLC9A1 (0.49) | SLC9A1KMT2AFASN | |
| SCHEMBL1763403 | 0.79 | FASN (0.50) | SLC9A1CYP2C9CYP2C19FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| WO-2010005783-A1 | PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | NHERF1, SLC9A1, SLC9A5 | SLC9A1 2/4885CYP2C9 1660/4885CYP2C19 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.